Medicare would cover at-home infusions for rare lung disorder starting 2027

What does this do?

HR 2343 would add home infusion augmentation therapy for Alpha-1 Antitrypsin Deficiency to the list of services covered under Medicare Part B, effective January 1, 2027. Augmentation therapy delivers a missing protein directly into the bloodstream to protect the lungs and liver. Currently, Medicare does not clearly cover this treatment when performed at home, which can require patients to travel to clinics or pay out of pocket.

Who does it affect?

Medicare enrollees with Alpha-1 Antitrypsin Deficiency who need regular infusion therapy to manage their emphysema would be directly affected, though the condition is rare. Home infusion therapy suppliers and nurses providing this service would also be affected, as the bill creates a clear Medicare billing pathway for this treatment.

Why does it matter?

Patients who currently lack clear Medicare coverage for home infusion may travel to medical facilities or pay out of pocket for each treatment. Establishing a billing pathway and payment structure would shift where and how this care is delivered and reimbursed.

What does it cost, and who pays?

• Medicare pays 80% of approved cost
• Patients owe remaining 20%
• Covers supplies plus up to 2 hrs nursing

Where does it stand?